IMPACT OF CNS DEPRESSANTS ON COGNITIVE FUNCTION IN PATIENTS WITH NEUROLOGICAL DISORDER AND COMORBIDITIES: A PROSPECTIVE CROSS-SECTIONAL STUDY

Background: Cognitive impairment is a serious problem, especially for the elderly. Cognitive impairment is often associated with neurological disorders and congenital diseases. The impact of central nervous system depressants (CNSDs) on cognition needs to be further investigated. Objective: This study aims to evaluate the relationship between CNSD use and cognitive impairment with neurological disorders and comorbidities, along with the severity of cognitive dysfunction. Materials and Methods: A prospective cross-sectional study was conducted over a 6-month period in a tertiary care hospital, including 129 patients aged 18 years and older. Cognitive function was assessed using a structured questionnaire and severity scales. Data on demographics, neurological disorders, medications, and comorbidities were collected from patient records and statistically analyzed. Results: Cognitive decline increased with age, particularly in patients aged 61+ years. Benzodiazepines were significantly associated with mild cognitive impairment. (22%, p = 0.02), while anti-convulsant and anti-Parkinsonian drugs had minimal impact. Stroke patients with comorbidities showed the highest rates of cognitive decline (25.3%, p = 0.01). Conclusion: The Results indicate that while CNS depressants may provide symptomatic relief, they also carry risks of further cognitive deterioration, particularly in vulnerable populations CNSDs, age, and comorbidities are key contributors to cognitive impairment. Early cognitive assessments and targeted management Strategies are crucial for improving outcomes. Further research is recommended. To establish causal links and explore long-term effects.